Literature DB >> 9307273

Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells.

H Yoshiji1, S R Harris, U P Thorgeirsson.   

Abstract

In this study, we used a self-contained tetracycline-regulated retroviral vector system to elucidate the role of vascular endothelial growth factor (VEGF) in controlling s.c. growth of human T-47D breast carcinoma cells. VEGF expression was tightly regulated by this system, both in vitro and in nude mouse xenografts. A 2.4-fold increase in tumor volume was associated with VEGF overexpression. Tumor growth was almost completely inhibited when VEGF was suppressed from the time of T-47D cell inoculation, and a 6-fold reduction in tumor volume was observed when VEGF suppression was started in 175-mm3 tumors. However, no growth inhibition was observed when VEGF suppression was started in 820-mm3 tumors. In these tumors, basic fibroblast growth factor and transforming growth factor alpha RNA expression was detected after VEGF was switched off. These findings demonstrate that VEGF is critical for the initial s.c. growth of T-47D breast carcinoma cells, whereas other angiogenic factors can compensate for the loss of VEGF after the tumors have reached a certain size.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307273

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Angiogenic molecules and mechanisms in breast cancer.

Authors:  I Wu; M A Moses
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.075

2.  Changes in vascularization of human breast cancer xenografts responding to antiestrogen therapy.

Authors:  C A Kristensen; L M Hamberg; G J Hunter; S Roberge; D Kierstead; G L Wolf; R K Jain
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

Review 3.  Causes and effects of heterogeneous perfusion in tumors.

Authors:  R J Gillies; P A Schornack; T W Secomb; N Raghunand
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

Review 4.  A role for antiangiogenic therapy in breast cancer.

Authors:  Marsha A Moses; Jay Harper; Cecilia A Fernández
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

5.  Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer.

Authors:  Peter Büchler; Howard A Reber; Mendel M Roth; Mark Shiroishi; Helmut Friess; Oscar J Hines
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

6.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

7.  Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment.

Authors:  Stefano Indraccolo; Laura Stievano; Sonia Minuzzo; Valeria Tosello; Giovanni Esposito; Erich Piovan; Rita Zamarchi; Luigi Chieco-Bianchi; Alberto Amadori
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

8.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.

Authors:  R K Jain; N Safabakhsh; A Sckell; Y Chen; P Jiang; L Benjamin; F Yuan; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Authors:  Scott Kopetz; Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

Review 10.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.